Maryland Medical Cannabis Affinity Group Monthly Meeting
March 1 at 9:00 am EST
Our next monthly meeting will be held on:
Friday, March 1st, 2019
9:00 AM - 11:00 AM
at Offit Kurman's Baltimore Office
300 E Lombard St, Suite 2010
Baltimore, MD 21202
Cannabis up North! Regulatory and IP Issues Under Canada's New Adult Use Market
David Wood from Borden Ladner Gervais will discuss Canadian cannabis regulatory and IP issues. The Canadian cannabis industry is in the headlines. Mergers and acquisitions, imminent adult use regulations and storefront sales, product diversification on the horizon, investment and validation from the beverage industry, and troubles at the US border are all regular features in the news. As the first G7 country moves forward on a new approach to mitigating the social and economic harms of drug abuse by regulating rather than prohibiting cannabis, opportunities and challenges are emerging – and being defined by participants. In this presentation, he will describe the industry and its regulations, and the role of intellectual property to protect and leverage technology and branding in this industry. The implications of regulating a product for sale both as a medicine and as a discretionary psychoactive product are further reaching than is immediately apparent – as is the opportunity. Responsible execution will be critical as the World watches Canada’s move forward from prohibition to regulation, and in many cases are following closely behind with spirited medical programs and talk of adult use regulations in other jurisdictions. Canadian regulations are a template for those in many other jurisdictions, particularly in quality control and process, for upstream, midstream and downstream aspects of the industry.
Partner at Borden Ladner Gervais
David Wood is co-chair of the Borden Ladner Gervais Cannabis Industry Focus Group. He is a partner, lawyer and patent agent, and holds a PhD in structural biochemistry. David practices intellectual property and regulatory law. His regulatory practice is specific to the Canadian cannabis industry and with a few exceptions, his entire practice is focused on the Canadian cannabis industry.
David advises federal cannabis licensees, technology companies and other domestic and foreign participants in the Canadian cannabis industry in relation to the their intellectual property rights, and their rights under Cannabis Act and its regulations, including the Cannabis Regulations and the Industrial Hemp Regulations. He advises clients both in the context of transactions and operationally, including during research and development. His understanding of the cannabis industry domestically and internationally has increased value both when advising entities focused entirely on the industry and when advising established entities from other sectors who are entering the industry.